An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines-Reference-Cited by-同舟云学术

An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines

Published:2021-05-11 Issue: Volume: Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Guo Yan¹,He Wenhui¹,Mou Huihui¹,Zhang Lizhou¹,Chang Jing¹,Peng Shoujiao¹,Ojha Amrita¹,Tavora Rubens¹,Parcells Mark S.²,Luo Guangxiang³^ORCID,Li Wenhui⁴,Zhong Guocai⁵⁶,Choe Hyeryun¹,Farzan Michael¹,Quinlan Brian D.¹

Affiliation:

1. Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, USA

2. Department of Animal and Food Sciences, University of Delaware, Newark, Delaware, USA

3. Department of Microbiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA

4. National Institute of Biological Sciences, Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China

5. Scripps Research SZBL Chemical Biology Institute, Shenzhen Bay Laboratory, Shenzhen, China

6. School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China

Abstract

All available vaccines for coronavirus disease 2019 (COVID-19) express or deliver the full-length SARS-CoV-2 spike (S) protein. We show that this antigen is not optimal, consistent with observations that the vast majority of the neutralizing response to the virus is focused on the S-protein receptor-binding domain (RBD).

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mBio.00930-21

Reference41 articles.

1. Origin and evolution of pathogenic coronaviruses

2. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

3. A pneumonia outbreak associated with a new coronavirus of probable bat origin